Replies to post #33417 on Biotech Values

[ghmm]

I also signed up late and appreciate you resending it!

Sorry if this has been mentioned before (I don't have search, subscribe to SI but not IHub)...

Any thoughts on InterMune's Protease Inhibitor Program or waiting to see how it does in Phase 1B? Their preclinical data seems very impressive even though they are behind Schering and Vertex. Wonder if anyone would consider combining PI's if ones are more resistant against certain variants then others?